Resonant Sensors

Resonant Sensors

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Resonant Sensors is a private biotechnology tools company commercializing a novel label-free biosensor platform for biologics discovery. Its core technology, guided-mode resonance (GMR), is embedded in disposable 96-well plates, allowing researchers to run 96 samples in parallel with small volumes to rapidly obtain kinetic binding data. The company targets the high-growth antibody discovery and characterization market, offering both its ResoSens instrument/consumables and related contract services through its affiliate, RSI Bioservices. Positioned as a benchtop alternative to traditional, more complex biosensor systems, Resonant Sensors aims to bring kinetic decision-making directly to discovery teams.

Medical DevicesDiagnostics

Technology Platform

Guided-Mode Resonance (GMR) photonic biosensor technology embedded in 96-well plates for label-free, real-time biomolecular interaction analysis and kinetic binding measurements.

Opportunities

The global surge in antibody and biologics development creates massive demand for high-throughput, information-rich screening tools.
Resonant Sensors' benchtop platform can democratize kinetic analysis, moving it from core facilities to individual discovery teams, capturing a growing segment of the market.
The recurring revenue model from disposable sensor plates and the complementary services business offer multiple paths for growth and customer lock-in.

Risk Factors

The company faces intense competition from established label-free technologies and alternative methods.
As a small player with a novel platform, achieving widespread market adoption and validation against gold-standard techniques is a significant challenge.
Scaling operations, manufacturing, and global support with limited resources presents an execution risk.

Competitive Landscape

Resonant Sensors competes in the label-free biosensor market against established giants like Cytiva (Biacore SPR systems) and Sartorius (Octet BLI systems). Its primary competitive differentiation is the 96-well parallel processing format and benchtop design, targeting higher throughput and easier accessibility than traditional SPR, while aiming to provide richer kinetic data than some BLI applications. It also competes with other plate-based screening methods (e.g., ELISA) by offering label-free, kinetic data.